Avak Kahvejian, Flagship Pioneering general partner

Am­per­sand snags $50M as Flag­ship fo­cus­es ther­a­peu­tics on de­sired tar­gets on­ly 

The be­he­moth biotech cre­ator Flag­ship Pi­o­neer­ing is out with an­oth­er start­up aim­ing to achieve the crown jew­el of drug de­vel­op­ment: treat­ments that hit on­ly the de­sired tar­get and cause no un­want­ed ef­fects else­where.

Am­per­sand Bio­med­i­cines is the Boston in­cu­ba­tor’s lat­est biotech to open its blinds, with Flag­ship dish­ing out a $50 mil­lion check to bankroll ini­tial work.

Lead­ing the charge at Am­per­sand is Flag­ship gen­er­al part­ner Avak Kahve­jian, who’s al­so found­ing CEO of Pro­Found Ther­a­peu­tics and has been in­volved in the ear­ly days of mul­ti­ple oth­er com­pa­nies formed by the en­gine that sparked Mod­er­na.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.